Suppr超能文献

鉴定垂体大腺瘤中的突变型 K-RAS。

Identification of mutant K-RAS in pituitary macroadenoma.

机构信息

Laboratório de Biomedicina do Cérebro, Instituto Estadual do Cérebro Paulo Niemeyer, Rua do Rezende156-Centro, Rio de Janeiro, 20231-092, Brazil.

Neurosurgery Division, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil.

出版信息

Pituitary. 2021 Oct;24(5):746-753. doi: 10.1007/s11102-021-01151-6. Epub 2021 May 5.

Abstract

PURPOSE

RAS genes are among the most frequently mutated genes in cancer, where their mutation frequency varies according to the distinct RAS isoforms and tumour types. Despite occurring more prevalent in malignant tumours, RAS mutations were also observed in few benign tumours. Pituitary adenomas are examples of benign tumours which vary in size and aggressiveness. The present study was performed to investigate, via liquid biopsy and tissue analysis, the presence of K-RAS mutations in a pituitary macroadenoma.

METHODS

Molecular analysis was performed to investigate K-RAS mutations using the droplet digital PCR (ddPCR) method by evaluating both plasma (liquid biopsy) and the solid tumour of a patient diagnosed with a giant clinically non-functioning pituitary tumour.

RESULTS

The patient underwent surgical resection due to visual loss, and the histopathological analysis showed a gonadotrophic pituitary macroadenoma. The molecular analysis revealed the presence of mutant K-RAS both in the plasma and in the tumour tissue which, to our knowledge, has not been previously reported in the literature.

CONCLUSION

Our findings highlight the exceptional capacity of the digital PCR in detecting low frequency mutations (below 1%), since we detected, for the first time, K-RAS mutations in pituitary macroadenoma. The potential impact of K-RAS mutations in these tumours should be further investigated.

摘要

目的

RAS 基因是癌症中最常发生突变的基因之一,其突变频率根据不同的 RAS 同工型和肿瘤类型而有所不同。尽管 RAS 突变在恶性肿瘤中更为常见,但在少数良性肿瘤中也观察到 RAS 突变。垂体腺瘤就是大小和侵袭性不同的良性肿瘤的一个例子。本研究通过液体活检和组织分析,旨在调查一种垂体大腺瘤中 K-RAS 突变的存在情况。

方法

采用液滴数字 PCR(ddPCR)方法对 K-RAS 突变进行分子分析,通过评估患有巨大无功能性临床垂体肿瘤的患者的血浆(液体活检)和实体瘤,对 K-RAS 突变进行评估。

结果

该患者因视力丧失而接受了手术切除,组织病理学分析显示为促性腺激素垂体大腺瘤。分子分析显示,无论是在血浆中还是在肿瘤组织中,都存在 K-RAS 突变,据我们所知,这在文献中尚未有过报道。

结论

我们的研究结果强调了数字 PCR 检测低频突变(低于 1%)的卓越能力,因为我们首次在垂体大腺瘤中检测到 K-RAS 突变。应该进一步研究 K-RAS 突变对这些肿瘤的潜在影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验